SIRT6 and hematopoietic and lymphoid system neoplasm: On the other hand, SIRT6-mediatedsuppression of ERK2 and p90RSK signaling increases resistanceto DNA-damaging therapeutics.76 Upregulationof SIRT6 has also been observed in other blood cancers, includingacute myeloid leukemia,77 chronic lymphocyticleukemia,78 and diffuse large B-cell lymphoma(DLBCL).79 In DLBCL cells, knockdown ofSIRT6 leads to higher sensitivity to chemotherapy, altered cell proliferation,augmented rates of apoptosis, and cell cycle arrest.